research Fesoterodine: Pharmacological properties and clinical implications
Fesoterodine is effective and safe for elderly patients with overactive bladder.
Search
for
Sort by
Research
60-90 / 1000+ resultsresearch 5 Alpha-reductase inhibitors: whatʼs new?
A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
research 5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction
5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.
research Discontinuation of Alpha-Blockade after Initial Treatment with Finasteride and Doxazosin for Bladder Outlet Obstruction
Stopping alpha-blocker medication after 6-9 months is safe and effective for most patients with bladder outlet obstruction.
research Editorial Comment
More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.
research Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
Tadalafil is effective for treating urinary symptoms in men with BPH.
research Adrenolytic and Vasodilator Therapy
New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.
research AB40. Sexual side effects of medical treatment of BPH
BPH treatments can cause sexual side effects affecting quality of life.
research Review: Dutasteride, fesoterodine, and finasteride are beneficial for lower urinary tract symptoms in older patients
Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
research Acute urinary retention: risks and management.
Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.
research Medikamentöse Therapie der BPH Ist eine Kombinationstherapie mit 5α-Reduktasehemmern und α-Rezeptorenblockern sinnvoll?
Combination therapy is more effective for prostate volumes over 60 ml.
research Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Selective non-steroidal inhibitors of 5α-reductase type 1
Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
research PD23-06 CHANGE IN SEXUAL FUNCTION IN MEN WITH LUTS/BPH ASSOCIATED WITH LONG-TERM TREATMENT WITH DOXAZOSIN, FINASTERIDE, AND COMBINED THERAPY
Long-term treatment with finasteride or combined therapy worsens sexual function in men with urinary issues.
research An overview on 5α-reductase inhibitors
5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
research Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis
Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
research Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
research Focus sulla finasteride: efficacia, meccanismi e raccomandazioni per l'uso clinico
Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
research 5‐α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population‐based cohort study
5α-reductase inhibitors do not increase anaemia risk compared to α-blockers in men with BPH.
research When two plus two must not equal four
Regulatory challenges make developing combination therapies in urology difficult and costly.
research Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis
Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
research MP45-12 CHRONIC ADMINISTRATION OF A LIMK2 INHIBITOR IMPROVES CAVERNOSAL VENO-OCCLUSIVE DYSFUNCTION THROUGH SUPPRESSION OF CAVERNOSAL FIBROSIS IN A RAT MODEL OF ERECTILE DYSFUNCTION AFTER CAVERNOSAL NERVE INJURY
Long-term use of certain prostate drugs can worsen erectile dysfunction by changing penile tissue, especially in rats with high blood pressure.
research Comparison of combination therapy with tamsulosin and dutasteride or finasteride in patients with benign prostatic hyperplasia: a randomized clinical trial
Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
research Influencia del tratamiento con alfa bloqueantes e inhibidores de la 5 alfa reductasa en los hallazgos morfológicos e inmunohistoquímicos de la hiperplasia benigna de próstata
Finasteride treatment makes the prostate look more like a healthy one.
research Medical Therapies for Treatment of BPH: Special Considerations in Elderly Men
Tailored treatment is crucial for elderly men with BPH due to potential risks and benefits of medications.
research High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Older patients sticking to their prostate medication saw lasting health benefits.
research Effect of dose reduction of dutasteride in combination with alpha-blockers in patients with lower urinary tract symptoms/benign prostatic enlargement
Taking dutasteride every other day works as well as daily and better preserves sexual function.
research Current treatment of BPH
TURP is the best treatment for BPH, but some patients prefer medications like alpha-blockers and finasteride.
research Dutasteride: a guide to its use as monotherapy in benign prostatic hyperplasia
Dutasteride effectively treats benign prostatic hyperplasia, improving symptoms and quality of life.
research Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase.
Dutasteride effectively treats enlarged prostate with manageable side effects.